The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 07, 2022

Filed:

Dec. 03, 2019
Applicant:

Oncoquest Inc., Edmonton, CA;

Inventors:

Christopher F. Nicodemus, Charlestown, MA (US);

Ragupathy Madiyalakan, Edmonton, CA;

Assignee:

Oncoquest Inc., Edmonton, CA;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 31/282 (2006.01); A61K 39/39 (2006.01); A61K 31/337 (2006.01); A61K 31/555 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01); C07K 14/47 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39558 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/555 (2013.01); A61K 39/00117 (2018.08); A61K 39/39 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07K 14/4748 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/3069 (2013.01); C07K 16/3092 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/55583 (2013.01); A61K 2039/585 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2319/30 (2013.01);
Abstract

The present document describes a method of inhibiting cancer tumor growth in a patient in need thereof, comprising at least a first treatment comprising steps a) and b): a) administering to the patient an immune adjuvant in combination with a therapeutic monoclonal antibody specific for a tumor associated antigen; and b) administering to the patient the immune adjuvant; and a final treatment consisting of administering to the patient the therapeutic monoclonal antibody specific for a tumor associated antigen, wherein time between step a) and step b) is a time sufficient for treatment of the patient with the immune adjuvant, and wherein time between the step b) and the final treatment is from about 10 to about 14 weeks.


Find Patent Forward Citations

Loading…